Publications - Craig B . Reeder, M.D.

Back to Research Profile

1. Piekarz RL, Frye R, Turner M, Wright JJ, Allen SL, Kirschbaum MH, Zain J, Prince HM, Leonard JP, Geskin LJ, Reeder C, Joske D, Figg WD, Gardner ER, Steinberg SM, Jaffe ES, Stetler-Stevenson M, Lade S, Fojo AT, Bates SE. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009 Nov 10; 27(32):5410-7. Epub 2009 Oct 13.
   View PubMed
2. Witzig TE, Wiernik PH, Moore T, Reeder C, Cole C, Justice G, Kaplan H, Voralia M, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis JB, Vose JM. Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma. J Clin Oncol 2009 Nov 10; 27(32):5404-9. Epub 2009 Oct 05.
   View PubMed
3. Kapoor P, Kumar S, Fonseca R, Lacy MQ, Witzig TE, Hayman SR, Dispenzieri A, Buadi F, Bergsagel PL, Gertz MA, Dalton RJ, Mikhael JR, Dingli D, Reeder CB, Lust JA, Russell SJ, Roy V, Zeldenrust SR, Stewart AK, Kyle RA, Greipp PR, Rajkumar SV. Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone. Blood 2009 Jul 16; 114(3):518-21. Epub 2009 Mar 26.
   View PubMed
4. Reeder CB, Reece DE, Kukreti V, Chen C, Trudel S, Hentz J, Noble B, Pirooz NA, Spong JE, Piza JG, Zepeda VH, Mikhael JR, Leis JF, Bergsagel PL, Fonseca R, Stewart AK. Cyclophosphamide, bortezomib and dexamethasone induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia 2009 Jul; 23(7):1337-41. Epub 2009 Feb 19.
   View PubMed
5. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB, North Central Cancer Treatment Group. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008 Jun; 49(6):1074-80.
   View PubMed
6. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008 Jun; 49(6):1074-80.
   View PubMed
7. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef INM, Laplant BR, Michalak JC, Salim M, Dalton RJ, Moore DF, Reeder CB. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group. Leukemia & Lymphoma 2008 Jun; 49(6):1074-80.
   View PubMed
8. Witzig TE, Geyer SM, Kurtin PJ, Colgan JP, Inwards DJ, Micallef IN, LaPlant BR, Michalak JC, Salim M, Dalton RJ, Moore DF Jr, Reeder CB, North Central Cancer Treatment Group. Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: a phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 2008 Jun; 49(6):1074-80.
   View PubMed
9. Czuczman MS, Reeder CB, Polikoff J, Chowhan NM, Esseessee I, Greenberg R, Ervin-Haynes A, Pietronigro D, Zeldis JB, Witzig TE. International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma. Journal of Clinical Oncology, 2008 Annual Meeting Proceedings (Post-Meeting Edition) 2008; 26(15S May 20 Suppl):8509.
   View PubMed
10. Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald GW. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide. Leuk Res 2007 Sep; 31(9):1185-9. Epub 2006 Nov 27.
    View PubMed
11. Zou YS, Fink SR, Stockero KJ, Paternoster SF, Smoley SA, Tun HW, Reeder CB, Tefferi A, Dewald GW. Efficacy of conventional cytogenetics and FISH for EGR1 to detect deletion 5q in hematological disorders and to assess response to treatment with Lenalidomide. Leukemia Research 2007 Sept; 31(9):1193-1197.
    View PubMed
12. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007 Mar; 82(3):323-41.
    View PubMed
13. Stewart AK, Bergsagel PL, Greipp PR, Dispenzieri A, Gertz MA, Hayman SR, Kumar S, Lacy MQ, Lust JA, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Reeder CB, Roy V, Kyle RA, Rajkumar SV, Fonseca R. A practical guide to defining high-risk myeloma for clinical trials, patient counseling and choice of therapy. Leukemia 2007 Mar; 21(3):529-34. Epub 2007 Jan 18.
    View PubMed
14. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R, Myelodysplastic Syndrome-003 Study Investigators. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 Oct 5; 355(14):1456-65.
    View PubMed
15. List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, Powell B, Greenberg P, Thomas D, Stone R, Reeder C, Wride K, Patin J, Schmidt M, Zeldis J, Knight R. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006 Oct 5; 355(14):1456-65.
    View PubMed
16. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dalton RJ, Carr AB, Kademani D, Keller EE, Viozzi Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 2006 Aug; 81(8):1047-53.
    View PubMed
17. Orrego M, Guo LS, Reeder C, De Petris G, Balan V, Douglas DD, Byrne T, Harrison E, Mulligan D, Rodriguez-Luna H, Moss A, Reddy K, Rakela J, Vargas HE. Hepatic B-cell non-Hodgkin's lymphoma of MALT type in the liver explant of a patient with chronic hepatitis C infection. Liver Transpl 2005 Jul; 11(7):796-9.
    View PubMed
18. Abraham RS, Charlesworth MC, Owen BAL, Benson LM, Katzmann JA, Reeder CB, Kyle RA. Trimolecular complexes of lambda light chain dimers in serum of a patient with multiple myeloma. Clin Chem 2002 Oct; 48(10):1805-11.
    View PubMed
19. Tefferi A, Li CY, Reeder CB, Geyer SM, Allmer C, Levitt R, Michalak JC, Addo F, Krook JE, Witzig TE, Schaefer PL, Mailliard JA. A phase II study of sequential combination chemotherapy with cyclophosphamide, prednisone, and 2-chlorodeoxyadenosine in previously untreated patients with chronic lymphocytic leukemia. Leukemia 2001 Aug; 15(8):1171-5.
    View PubMed
20. Reeder CB, Conley CR. CD5+ persistent polyclonal B-cell lymphocytosis in a male. Leukemia & Lymphoma 1999 May; 33(5-6):593-6.
    View PubMed
21. Harold KL, Schlinkert RT, Mann DK, Reeder CB, Noel P, Fitch TR, Braich TA, Camoriano JK. Long-term results of laparoscopic splenectomy for immune thrombocytopenic purpura. Mayo Clin Proc 1999 Jan; 74(1):37-9.
    View PubMed
22. Schlinkert RT, de la Garza-Grahm M, Reeder CB, Weiland LH, Beart RW Jr, Gleich GJ, Kephart GM, de Groen PC. Eosinophil-mediated bile duct stricture. Arch Pathol Lab Med 1992 Nov; 116:1241-3.
    View PubMed
23. Reeder CB, Connolly SM, Winkelmann RK. The evolution of Hodgkin's disease and necrobiotic xanthogranuloma syndrome. Mayo Clin Proc 1991 Dec; 66(12):1222-4.
    View PubMed
24. Dispenzieri A, Rajkumar SV, Gertz MA, Fonseca R, Lacy MQ, Bergsagel PL, Kyle RA, Greipp PR, Witzig TE, Reeder CB, Lust JA, Russell SJ, Hayman SR, Roy V, Kumar S, Zeldenrust SR, Dalton RJ, Stewart AK. Treatment of newly diagnosed multiple myeloma based on Mayo Stratification of Myeloma and Risk-adapted Therapy (mSMART): consensus statement. Mayo Clin Proc 2007 Mar; 82(3):323-41.
    View PubMed